To test whether CRISPR/Cas9 gene editing would affect the effector function of the T cells, the anti-tumor activity was tested by challenging the TCR/CD3neg CAR19 T cells with CD19+ Nalm6 leukemia cells. This evidence concerns the gene CD19 and leukemia.